Shedding of the endothelial surface layer in patients with aneurysmal subarachnoid hemorrhage

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00009724

Enrollment

Registered

2015-12-14

Start date

2016-05-07

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

I60.9 I67.1

Interventions

Group 1: Observational study - daily examinations of serum and cerebrospinal fluid during the first 14 days of hospitalization of all patients. Primary endpoint are serum levels of heparan sulfate and

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Acute subarachnoid hemorrhage due to vascular aneurysm treated on a neurosurgical intensive care unit.

Exclusion criteria

Exclusion criteria: Rejection of participation, any cancer, regular use of immune suppressing drugs, history of stroke or TIA in the last three months.

Design outcomes

Primary

Measure	Time frame
Time course of markers for endothelial shedding of the glycocalyx and potential modulating interacting factors in serum (heparansulfate, syndecan-1) and cerebrospinal fluid (adiponectin, leptin) during the first 14 days of hospitalization	—

Secondary

Measure	Time frame
Influence of clinical treatment on the course of the glycocalyx-shedding.	—

Countries

Germany

Contacts

Public ContactThorsten Annecke

Klinik für Anästhesiologie und Operative Intensivmedizin

Thorsten.Annecke@uk-koeln.de0221-478-0

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026